Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Nov 23;28(50):8015-25. doi: 10.1016/j.vaccine.2010.08.106. Epub 2010 Oct 8.

NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets.

Author information

  • 1Wadsworth Center, New York State Department of Health, State University of New York, Albany, NY 12201, United States.

Abstract

Although vaccines against influenza A virus are the most effective method to combat infection, it is clear that their production needs to be accelerated and their efficacy improved. We generated live attenuated human influenza A vaccines (LAIVs) by rationally engineering mutations directly into the genome of a pandemic-H1N1 virus. Two LAIVs (NS1-73 and NS1-126) were based on the success of LAIVs for animal influenza A viruses. A third candidate (NSΔ5) is a unique NS-mutant that has never been used as a LAIV. The vaccine potential of each LAIV was determined through analysis of attenuation, interferon production, immunogenicity, and their ability to protect mice and ferrets. This study demonstrates that NSΔ5 is an ideal LAIV candidate, provides important information on the effects that different NS mutations have on the pandemic-H1N1 virus and shows that LAIVs can be engineered directly from the genomes of emerging/circulating influenza A viruses.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
20934458
[PubMed - indexed for MEDLINE]
PMCID:
PMC2991506
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk